Lonza

Weekend Reading: Enhancing bioavailability for better delivery outcomes🚀 Did you know that an estimated 80% of small-molecule drug candidates suffer from low solubility and poor bioavailability? This challenge can prolong development timelines and increase costs, especially for vital medications in oncology, antivirals, and anti-inflammatory areas. The good news? Advanced formulation strategies are key to overcoming these hurdles! For small and emerging biotechs, Lonza serves as an essential strategic partner. We bring the experience, expertise, and advanced technologies needed to significantly enhance drug solubility and absorption. As our colleague Adi Kaushal recently highlighted when discussing Amorphous Solid Dispersions (ASDs) and bioavailability, these cutting-edge approaches are vital for converting crystalline drugs to a more soluble amorphous form, most commonly through spray drying or hot-melt extrusion. With patients increasingly preferring convenient oral medications, tackling these solubility issues head-on is crucial for bringing innovative therapies to market faster. Read the full report to explore how advanced formulation can revolutionize drug development and enhance bioavailability: https://ow.ly/Vsow50WvZzX #DrugDevelopment #Biotech #Lonza #Formulation #DrugSolubility #Bioavailability #HealthcareInnovation

Is poor solubility hindering your drug candidate? Watch our webinar on-demand, "Amorphous Solid Dispersions (ASDs): Pre-clinical to Commercial Capabilities," and learn from Lonza expert David Lyon, Executive Director, Senior Fellow Research. In this webinar, you'll learn how to: * Strategically evaluate ASDs for early-phase compounds. * Bridge the gap from preclinical screens to successful commercialization. * Accelerate your poorly soluble drug's journey to patients. Don't let solubility challenges hold you back. Watch our webinar on-demand and transform your drug development pipeline: https://ow.ly/XzwI50Wxik4 #ASD #DrugDevelopment #Solubility

Fabio Montagner recently spoke to The Pharmaceutical Post about the challenges in choosing the right packaging for biologics, and how getting it right first time is crucial as it can affect a drug's stability and efficacy. Read the full article here: https://lnkd.in/eDYK-srD #Lonza #CDMO #Biologics #DrugProduct

What if an mRNA spray could prevent your next asthma attack—or protect you in a pandemic? In this episode of A View On, Ethris CEO Carsten Rudolph shares how their inhalable, room temperature-stable mRNA therapy in development targets the lungs’ immune response. Listen to the full episode here, or wherever you usually find your podcasts: https://lnkd.in/dpUJdVg8 #mRNA #RespiratoryHealth #Biotech #PandemicPreparedness #Etris #Lonza #Podcast 

Weekend Reading: Navigating drug development and regulatory approval just got easier 🚀 Our latest executive summary distills the most crucial takeaways from our recent "End-to-end regulatory CDMO solutions" webinar. Perfect for busy professionals, it’s your ideal weekend reading. Authored by experts Praveenkumar Devakadaksham and Roché Walliser, this summary quickly helps you grasp: * Demystified regulatory expectations * Global expertise from the Lonza Advanced Synthesis team * Strategies to overcome dossier challenges Download it now to see how Lonza can help you achieve seamless development, manufacturing, and regulatory approval: https://ow.ly/UvTf50Wv5Uo #DrugDevelopment #RegulatoryAffairs #CDMO

In 2024, Martina joined Lonza as a Business Development Specialist, bringing her background in neuroscience & electrophysiology research into a new, fast-paced world. “While I am passionate about science, I thrive in the dynamic, social, and fast-paced environment of commercial roles.” After pivoting from academia to technical sales, she discovered a love for strategy, connection, and helping others bring their innovations to life. At Lonza, she now supports early-stage biotech companies, bridging the gap between groundbreaking research and real-world therapies. “Some startups might find working with Lonza intimidating. My role is to reassure them: we understand their challenges and can support them at every stage, starting from early phases of drug development.” Her journey is proof that with the right mindset and support, science can lead anywhere. “Whether you're social, creative, or strategic, there’s always a way forward.” #Lonza #Careers #CareerGrowth  Learn more about careers at Lonza: https://lnkd.in/gj8JnVy

We have seen a strong financial performance in H1 2025, with CHF 3.6 billion sales resulting in 19.0% CER sales growth, and a CORE EBITDA of CHF 1.1 billion resulting in a robust margin of 29.6%. In this context, we expect the CDMO business to deliver above guidance for the Full Year and have adjusted our CDMO Outlook for FY 2025 to CER sales growth of 20-21% and a CORE EBITDA margin of 30-31%. Performance in the CDMO business was supported by good operational execution, disciplined cost management and maturing growth projects. Two facilities in Visp (CH) commenced operations in H1, and we saw continuing customer interest in the Vacaville (US) site with further signings in negotiation. Read more about our progress in H1 2025 here: https://lnkd.in/djBvM_5Z #CDMO #Lonza #Growth #PharmaceuticalManufacturing #Biotech

Three experts from our Lonza site in Bend, Oregon recently presented a webinar on the development of dry powders for inhaled delivery. While these formulations are commonly used to treat respiratory conditions like asthma and COPD, they also hold promise for delivering poorly soluble drugs and even biologics via the lungs or intranasal route. Mariam Ibrahim, Beatriz Noriega Fernandes, PhD, and Rui Cruz explored the critical properties that influence successful inhaled delivery and how to select the most suitable manufacturing approach. For soluble small molecules that form stable crystals, micronization may be the preferred option. For poorly soluble compounds or biologics, spray drying to form an amorphous solid dispersion is often more effective. If you missed the live event, the webinar is now available on demand: https://ow.ly/A6m450WsIHr Interested in learning how our Bend team can support your inhaled formulation needs? Please reach out to us and we are happy to connect! #InhalationWebinar #AdvancedSynthesis #CDMO #Lonza

Unlock success in the rapidly expanding Antibody-Drug Conjugate (ADC) market. Lonza provides comprehensive, integrated solutions to simplify your value chain and accelerate your timeline to market. Want to gain deeper insights into optimizing your ADC development and manufacturing? Our colleague, Charles Johnson, Senior Director, Commercial Development, shares invaluable expertise in our webinar on-demand: "Lonza's integrated ADC offering: From concept to commercialization." Discover how to navigate complexities and accelerate your time to market. Click to watch now: https://ow.ly/3Mbz50Wsqwm #ADCs #Biopharma #Manufacturing #Lonza

Join our speakers Marta Margutti and Soenke Stocker at mRNA - Based Therapeutics Summit as they present "What it takes to manufacture in vivo CAR-T therapies - Manufacturing and Characterization considerations" 📅Tuesday, 22 July 🕧 12:00 - 12:30 EDT Learn more: https://lnkd.in/ekvueFm